• Pharma
  • April 30, 2022
USFDA approves this oral heart disease drug

Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration (USFDA) approved its oral heart disease drug Mavacamten, making it the first cardiac myosin inhibitor to be permitted for use in the…

  • Pharma
  • May 24, 2021
Bharat Parenterals gets DCGI nod for Favipiravir oral suspension

Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients. The company has received licence…

  • Pharma
  • May 20, 2021
Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir

Optimus Pharma received DCGI nod for conducting Phase III clinical trials for orally administered Molnupiravir capsules on patients with mild to moderate C-19 patients. After developing the active pharma ingredient (API) and the formulations for the product, Optimus…